Update on the Diagnosis and Treatment of Gout Based on Guidelines

doi:10.12114/j.issn.1007-9572.2018.00.059

Abstract

Abstract: The study of gout is going deep and the guideline for the management of gout from the British Society for Rheumatology and the management of acute and recurrent gout：a clinical practice guideline from the American College of Physicians were published recently cover the essentials such as the diagnosis of gout，timing for the initiation of therapy，therapies for acute and chronic gout and precautions in the management.Moreover，updates of diagnosis of the genetic level of gout are embodied by newly found risk loci for gout and ultrasound becoming a promising new imaging modality for gout.Furthermore，two uric acid-lowering agents，Lesinurad and Arhalofenate，have been used for the treatment of gout.This article interprets the updated guidelines and reviews the recent developments in gout diagnosis and management，in order to provide a theoretical reference for clinical treatment and preclinical research.

Key words: Gout, Guidebooks, Diagnosis, Genes, Ultrasonography

摘要： 随着对痛风研究的不断深入，2016—2017年发布了《英国风湿病学会（BSR）痛风管理指南》和《美国临床医师协会（ACP）临床实践指南：急性和复发性痛风管理》，包括对痛风的诊断、启动治疗的时机、急性期和慢性期的治疗方法、注意事项等。关于痛风诊断基因层面的研究逐渐增多，许多新的基因位点被发现；超声诊断对临床诊断痛风有一定的价值；降尿酸药物Lesinurad和Arhalofenate可以被用于治疗痛风。本文通过对指南进行解读，对痛风诊断和药物治疗的进展进行综述，以期为痛风治疗方法和药物研究提供理论支持。

关键词: 痛风, 指南, 诊断, 基因, 超声检查

CAO Wen,CHEN Guofang,LIU Chao. Update on the Diagnosis and Treatment of Gout Based on Guidelines[J]. Chinese General Practice, 2018, 21(32): 3920-3923. DOI: 10.12114/j.issn.1007-9572.2018.00.059.
曹雯,陈国芳,刘超. 基于指南的痛风诊治进展[J]. 中国全科医学, 2018, 21(32): 3920-3923. DOI: 10.12114/j.issn.1007-9572.2018.00.059.

References

［1］HUI M，CARR A，CAMERON S，et al．The British Society for Rheumatology guideline for the management of gout［J］．Rheumatology（Oxford），2017，56（7）：1246．DOI：10.1093/rheumatology/kex250.3922
［2］JANSEN T L，JANSEN M.The American College of Physicians and the 2017 guideline for the management of acute and recurrent gout：treat to avoiding symptoms versus treat to target［J］．Clin Rheumatol，2017，36（11）：2399-2402．DOI：10.1007/s10067-017-3840-1.3922
［3］JORDAN K M，CAMERON J S，SNAITH M，et al．British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout［J］．Rheumatology（Oxford），2007，46（8）：1372-1374．DOI：10.1093/rheumatology/kem056a.3922
［4］KHANNA D，FITZGERALD J D，KHANNA P P，et al．2012 American College of Rheumatology guidelines for management of gout.Part 1：systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia［J］．Arthritis Care Res（Hoboken），2012，64（10）：1431-1446．DOI：10.1002/acr.21772.3923
［5］KHANNA D，KHANNA P P，FITZGERALD J D，et al．2012 American College of Rheumatology guidelines for management of gout.Part 2：therapy and antiinflammatory prophylaxis of acute gouty arthritis［J］．Arthritis Care Res（Hoboken），2012，64（10）：1447-1461．DOI：10.1002/acr.21773.3923
［6］HAMBURGER M，BARAF H S，ADAMSON T C 3rd，et al．2011 recommendations for the diagnosis and management of gout and hyperuricemia［J］．Phys Sportsmed，2011，39（4）：98-123．DOI：10.3810/psm.2011.11.1946.3923
［7］JONES G，PANOVA E，DAY R.Guideline development for the management of gout：role of combination therapy with a focus on lesinurad［J］．Drug Des Devel Ther，2017，11：3077-3081．DOI：10.2147/DDDT.S97959.3923
［8］BEN SALEM C，SLIM R，FATHALLAH N，et al．Drug-induced hyperuricaemia and gout［J］．Rheumatology（Oxford），2017，56（5）：679-688．DOI：10.1093/rheumatology/kew293.3923
［9］CADZOW M，MERRIMAN T R，DALBETH N.Performance of gout definitions for genetic epidemiological studies：analysis of UK Biobank［J］．Arthritis Res Ther，2017，19（1）：181．DOI：10.1186/s13075-017-1390-1.3923
［10］MERRIMAN T.Genomic influences on hyperuricemia and gout［J］．Rheum Dis Clin North Am，2017，43（3）：389-399．DOI：10.1016/j.rdc.2017.04.004.3923
［11］LI Z，ZHOU Z，HOU X，et al．Replication of gout/urate concentrations GWAS susceptibility loci associated with gout in a Han Chinese population［J］．Sci Rep，2017，7（1）：4094．DOI：10.1038/s41598-017-04127-4.3923
［12］DALBETH N，STAMP L K，MERRIMAN T R.The genetics of gout：towards personalised medicine?［J］．BMC Med，2017，15（1）：108．DOI：10.1186/s12916-017-0878-5.3923
［13］张亚弟，张翻弟，赵丽，等．SLC22A12基因rs1529909和rs7929627位点多态性与高尿酸血症的相关性［J］．卫生研究，2017，46（4）：589-594.3923
ZHANG Y D，ZHANG F D，ZHAO L，et al．Association between SLC22A12 rs1529909 and rs7929627 polymorphism and hyperuricemia［J］．Journal of Hygiene Research，2017，46（4）：589-594.3923
［14］HIGASHINO T，MATSUO H，OKADA Y，et al．A common variant of MAF/c-MAF，transcriptional factor gene in the kidney，is associated with gout susceptibility［J］．Hum Cell，2018，31（1）：10-13．DOI：10.1007/s13577-017-0186-6.3923
［15］ZHU Z，MENG W，LIU P，et al．DNA hypomethylation of a transcription factor binding site within the promoter of a gout risk gene NRBP1 upregulates its expression by inhibition of TFAP2A binding［J］．Clin Epigenetics，2017，9：99．DOI：10.1186/s13148-017-0401-z.3923
［16］陶金辉，唐江平，程苗，等．P2X7R基因rs1621388多态性与痛风易感性的关联研究［J］．中华疾病控制杂志，2017，21（7）：698-701，736．DOI：10.16462/j.cnki.zhjbkz.2017.07.012.TAO J H，TANG J P，CHENG M，et al．Study on the association between P2X7R gene rs1621388 polymorphism and gout susceptibility［J］．Chinese Journal of Disease Control & Prevention，2017，21（7）：698-701，736．DOI：10.16462/j.cnki.zhjbkz.2017.07.012.3923
［17］高泽燕，吕珂.高尿酸血症诊治中超声应用价值及进展［J］．中国医学科学院学报，2017，39（2）：280-284．DOI：10.3881/j.issn.1000-503X.2017.02.019.3923
GAO Z Y，LYU K.Value and progress of ultrasound in diagnosis and treatment of hyperuricemia［J］．Acta Academiae Medicinae Sinicae，2017，39（2）：280-284．DOI：10.3881/j.issn.1000-503X.2017.02.019.3923
［18］ABHISHEK A.New urate-lowing therapies［J］．Curr Opin Rheumatol，2018，30（2）：177-182．DOI：10.1097/BOR.0000000000000476.3923
［19］DAVIES K，BUKHARI M A S.Recent pharmacological advances in the management of gout［J］．Rheumatology（Oxford），2018，57（6）：951-958．DOI：10.1093/rheumatology/kex343.3923
［20］HOY S M.Lesinurad：first global approval［J］．Drugs，2016，76（4）：509-516．DOI：10.1007/s40265-016-0550-y.3923
［21］MINER J，TAN P K，HYNDMAN D，et al．Lesinurad，a novel，oral compound for gout，acts to decrease serum uric acid through inhibition of urate transporters in the kidney［J］．Arthritis Res Ther，2016，18（1）：214．DOI：10.1186/s13075-016-1107-x.3923
［22］GUPPTA A，SHARMA P K，MISRA A K，et al．Lesinurad：a significant advancement or just another addition to existing therapies of gout?［J］．J Pharmacol Pharmacother，2016，7（4）：155-158．DOI：10.4103/0976-500X.195897.3923
［23］PRREZ-RUIZ F，SUNDY J S，MINER J N，et al．Lesinurad in combination with allopurinol：results of a phase 2，randomised，double-blind study in patients with gout with an inadequate response to allopurinol［J］．Ann Rheum Dis，2016，75（6）：1074-1080．DOI：10.1136/annrheumdis-2015-207919.3923
［24］TAUSCHE A K，ALTEN R，DALBETH N，et al．Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor：a 6 month phase 3 clinical trial and extension study［J］．Rheumatology（Oxford），2017，56（12）：2170-2178．DOI：10.1093/rheumatology/kex350.3923
［25］STEINBERG A S，VINCE B D，CHOI Y J，et al．The pharmacodynamics，pharmacokinetics，and safety of Arhalofenate in combination with febuxostat when treating hyperuricemia associated with gout［J］．J Rheumatol，2017，44（3）：374-379．DOI：10.3899/jrheum.161062.3923

[1]	WANG Tingting, TANG Yong, ZHANG Wenke, LI Zhigang. Research Progress on Exercise Intervention of Hyperuricemia [J]. Chinese General Practice, 2025, 28(30): 3841-3846.
[2]	LI Hao, LI Peijin, LIU Tingting, CUI Yiyuan, LI Sicong, LIU Lixing, FENG Li, Working Group on Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment Guidelines for Cancer Pain. Guidelines on the Diagnosis and Treatment of Cancer Pain by Integrated Traditional Chinese and Western Medicine [J]. Chinese General Practice, 2025, 28(30): 3729-3740.
[3]	ZHOU Sheng, DENG Changsheng, ZOU Guanyang, SONG Jianping. Research Progress on the Pathogenesis of Complications of Malaria in Cardiovascular Diseases [J]. Chinese General Practice, 2025, 28(27): 3466-3472.
[4]	YANG Jun, MAIBUBAIMU· Aisikaer, YANG Qianqian, LI Kai, YIN Gaojun, CAI Huizhen. Effects of Frequent Diets on Glucolipid Metabolism and Biorhythmic Expression in Humans [J]. Chinese General Practice, 2025, 28(27): 3432-3440.
[5]	ZHI Congcong, LI Xue, CHENG Yicheng, WANG Xiaolong, ZHENG Lihua. Guidelines for Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment of Hemorrhoids (2025 Edition) [J]. Chinese General Practice, 2025, 28(26): 3217-3228.
[6]	PAN Qi, REN Jingjing, MA Fanghui, HU Mengjie. Survey of General Practitioners' Cognition and Needs for AI Assisted Diagnosis and Treatment Systems [J]. Chinese General Practice, 2025, 28(25): 3127-3136.
[7]	WEI Yunhong, YANG Li, WANG Yulu, YE Qiufang, DAI Anni, HE Yan. Study on Cardiopulmonary Function During Different Exercise Stages in Patients with Obesity-related Hypertension [J]. Chinese General Practice, 2025, 28(24): 2972-2978.
[8]	Chinese Geriatrics Society, General Practice Branch of Zhejiang Medical Association, the Expert Collaboration Group on Medically Unspecified Disease in General Practice. Expert Consensus on the Diagnosis, Treatment, and Management of Emaciation (2025) [J]. Chinese General Practice, 2025, 28(21): 2577-2594.
[9]	LIU Hongya, YU Dehua. Construction and Practice of Clinical Diagnosis and Treatment Technology Combining General Practice and Specialist in Shanghai Community [J]. Chinese General Practice, 2025, 28(19): 2390-2397.
[10]	BIAN Ying, YIN Gang, ZHANG Zixun, TAO Hongbing. The Mechanism of Information Construction Enabling High-quality Development of Compact County-level Medical Consortium [J]. Chinese General Practice, 2025, 28(19): 2426-2432.
[11]	DENG Yaqian, CAO Chunli, MA Jinmei, LI Wenxiao, XU Zelin, CHENG Jing, LI Jun. Predictive Value of S-Detect Combined with Virtual Touch Tissue Imaging Quantification in Axillary Lymph Node Metastasis of Breast Cancer [J]. Chinese General Practice, 2025, 28(17): 2149-2155.
[12]	CHEN Beibei, LI Jia, TAN Wenbin. Progress in the Research of Endocrine and Metabolic System Diseases and Secondary Osteoporosis [J]. Chinese General Practice, 2025, 28(17): 2082-2091.
[13]	LI Jie, DU Yue, SHAO Shen, PAN Dong, ZHANG Yaxin. The Operational Efficiency of Traditional Chinese Medicine Diagnosis and Treatment Services in Primary Medical Institutions in Tianjin Based on DEA and SFA [J]. Chinese General Practice, 2025, 28(16): 1980-1986.
[14]	GU Jie, HUANG Yanyan. Diagnosis and Comprehensive Management of Rare Diseases: the Indispensable Role of General Practitioners [J]. Chinese General Practice, 2025, 28(16): 1955-1960.
[15]	CHEN Dian, LONG Huanyu, ZHANG Congxi, CHU Lanhe, LI Shurun, CHEN Yahong. Interpretation of Global Strategy for the Diagnosis, Treatment, Management and Prevention of Chronic Obstructive Pulmonary Disease 2025 Report [J]. Chinese General Practice, 2025, 28(16): 1937-1949.